Psychemedics Corporation

Equities

PMD

US7443752057

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
2.55 USD +0.39% Intraday chart for Psychemedics Corporation -0.78% -13.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Psychemedics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Tech in Focus on -2- DJ
North American Morning Briefing : Investors -2- DJ
Psychemedics Corporation Announces Relocation of its Corporate Headquarters to Dallas, Texas CI
Psychemedics Relocates Headquarters to Dallas; Shares Rise MT
Tranche Update on Psychemedics Corporation's Equity Buyback Plan announced on March 18, 2008. CI
Earnings Flash (PMD) PSYCHEMEDICS CORPORATION Posts Q3 Revenue $5.7M MT
Psychemedics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer CI
Psychemedics Names Chief Revenue Officer MT
Psychemedics Corporation Announces Charles Doucot, to Leave as Executive Vice President, Effective September 15, 2023 CI
Tranche Update on Psychemedics Corporation's Equity Buyback Plan announced on March 18, 2008. CI
Earnings Flash (PMD) PSYCHEMEDICS CORPORATION Posts Q2 Revenue $5.5M MT
Psychemedics Corporation Determines to Eliminate the Dividend CI
Psychemedics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Psychemedics Corporation Announces Board Changes CI
Psychemedics Corporation Announces CEO Changes CI
Psychemedics Says Brian Hullinger to Succeed Ray Kubacki as CEO, Effective Aug. 17 MT
Tranche Update on Psychemedics Corporation's Equity Buyback Plan announced on March 18, 2008. CI
Earnings Flash (PMD) PSYCHEMEDICS CORPORATION Posts Q1 Revenue $5.9M MT
Psychemedics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Psychemedics Corporation Declares Cash Dividend, Payable on June 8, 2023 CI
Tranche Update on Psychemedics Corporation's Equity Buyback Plan announced on March 18, 2008. CI
Earnings Flash (PMD) PSYCHEMEDICS CORPORATION Posts Q4 Revenue $5.7M MT
Psychemedics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Chart Psychemedics Corporation
More charts
Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet.
More about the company
  1. Stock Market
  2. Equities
  3. PMD Stock
  4. News Psychemedics Corporation
  5. Psychemedics Relocates Headquarters to Dallas; Shares Rise